Forty Seven raises $75M series B

Forty Seven Inc. (Palo Alto, Calif.) raised $75 million in a series B round led by new investor Wellington Management Company LLP. Existing investors Clarus, Lightspeed Venture Partners, Sutter Hill Ventures, and GV also participated.

Formed in 2015 to develop inhibitors of CD47 for cancer, Forty Seven has an exclusive, worldwide license from Stanford University to lead candidate Hu5F9-G4 and multiple preclinical immuno-oncology programs (see BioCentury Innovations, Aug. 25, 2016)...